<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561350</url>
  </required_header>
  <id_info>
    <org_study_id>MISC-MSI</org_study_id>
    <nct_id>NCT03561350</nct_id>
  </id_info>
  <brief_title>Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing</brief_title>
  <official_title>Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Minimally Invasive Surgery Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Minimally Invasive Surgery Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The method to analyze the microsatellite instability (MSI) status by next-generation
      sequencing (NGS) has been established to assess the deficiency of DNA mismatch repair (MMR)
      system. The aim of our study is to evaluate the feasibility and reliability of this NGS
      method by testing the circulating tumor DNA (ctDNA) in blood sample of advanced colorectal
      cancer patients. If the result is positive, the MSI status could be easily learned without
      the acquisition of tissue samples.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">September 28, 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MSI status in blood sample</measure>
    <time_frame>through study completion, an average of 1 year</time_frame>
    <description>ctDNA and leucocyte are extracted from blood sample for MSI detection by ColonCore NGS panel (Burning Rock, Guangzhou, China). There are three types of MSI status, MSI-H, MSI-L and MSS.</description>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Colorectal Neoplasms</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample of advanced colorectal cancer patients
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients hospitalized in Shanghai Minimally Invasive Surgery Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a biopsy proven histological diagnosis of colorectal carcinoma

          -  MSI status of tissue sample known by IHC or PCR method

          -  willing to participate and informed consent signed

        Exclusion Criteria:

          -  history of other malignant tumors

          -  patients with inflammatory bowel disease

          -  patients with familial adenomatous polyposis

          -  patients treated by surgery or adjuvant treatment

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhenghao CAI</last_name>
    <phone>86-21-64458887</phone>
    <email>czh12005@rjh.com.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Minimally Invasive Surgery Canter, Ruijin hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenghai CAI, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>June 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>June 16, 2018</last_update_submitted>
  <last_update_submitted_qc>June 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microsatellite Instability</keyword>
  <keyword>Circulating Tumor DNA</keyword>
  <keyword>Colorectal Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

